Mar 14, 2016 11:16 am UTC| Business
Dublin, March 14, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/7wgl4v/global_lignin) has announced the addition of the "Global Lignin Market Report" report to their offering. ...
Kandi Technologies Reports Fourth Quarter and Full Year 2015 Financial Results
Mar 14, 2016 11:02 am UTC| Business
-Q4 EV parts sales increased 51.6% YoY to $57.5 million- 2015 EV parts sales increased 68.4% YoY to $196.1 million- Q4 the JV Company sold 12,100 EV products, a 231.0% increase YoY- 2015 the JV Company sold 24,220 EV...
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)
Mar 14, 2016 11:00 am UTC| Business
- Study in the treatment of Dravet syndrome – a rare and severe form of epilepsy in children with no FDA-approved treatments - - Primary endpoint achieved with high statistical significance (p=0.01) showing that...
Cellular Biomedicine Group Reports Full-Year 2015 Financial Results and Recent Operational Progress
Mar 14, 2016 11:00 am UTC| Business
- Achieved first clinical milestones for CD19, CD20, CD30 and EGFR CAR-T cell assets- Expanded Immuno-Oncology platform with key acquisitions- Expanded Stem Cell platform with the launch of new autologous and allogeneic...
Mar 14, 2016 11:00 am UTC| Business
REDWOOD CITY, Calif., March 14, 2016 -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs,...
Mar 14, 2016 11:00 am UTC| Business
Positive Initial Phase 1 ZYN002 Single Rising Dose Results Reported; Phase 1 Multiple Rising Dose Trial Underway FDA Grants ZYN002 Orphan-Drug Designation for Fragile X Syndrome Three ZYN002 Phase 2a Trials Planned for...
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
Mar 14, 2016 11:00 am UTC| Business
NEW YORK, March 14, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative...